Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis

被引：22
|
作者：
Prieto-Perez, Rocio [1 ]
Llamas-Velasco, Mar [2 ]
Cabaleiro, Teresa [1 ,3 ]
Solano-Lopez, Guillermo [2 ]
Marquez, Beatriz [4 ]
Roman, Manuel [1 ]
Ochoa, Dolores [1 ]
Talegon, Maria [1 ]
Dauden, Esteban [2 ]
Abad-Santos, Francisco [1 ,3 ]
机构：
[1] UAM, Inst Invest Sanitaria Princesa IP, Inst Teofilo Hernando, Clin Pharmacol Serv,Hosp Univ Princesa, Madrid, Spain
[2] Hosp Univ Princesa, Inst Invest Sanitaria Princesa, Dermatol Serv, Madrid, Spain
[3] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
[4] Hosp Univ Gregorio Maranon, Clin Biochem Serv, Madrid, Spain
来源：
PHARMACOGENOMICS | 2017年 / 18卷 / 02期
关键词：
pharmacogenetics; psoriasis; ustekinumab; GENOME-WIDE ASSOCIATION; FUNCTIONAL VARIANTS; SUSCEPTIBILITY LOCI; CLINICAL-RESPONSE; CROHNS-DISEASE; POLYMORPHISMS; GENE; THERAPY; EFFICACY; DELETION;
D O I：
10.2217/pgs-2016-0122
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim/Materials & methods: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with ustekinumab. We evaluated 121 polymorphisms to study a possible association between these SNPs and the response to ustekinumab (PASI75 at 4 months; n = 69). Results/Conclusion: The adjusted results (false discovery rate) showed an association between five SNPs in TNFRSF1A, HTR2A, NFKBIA, ADAM33 and IL13 genes, and poor response to ustekinumab. Furthermore, six SNPs in CHUK, C17orf51, ZNF816A, STAT4, SLC22A4 and Corf72 genes were associated with better response to ustekinumab. However, there was no significant association between response to ustekinumab and SNPs in HLA-C as it has been recently described. Finally, a higher weight was obtained in nonresponders than responders (p = 0.018). Further studies would be necessary to be closer to personalized medicine.
引用
收藏
页码：157 / 164
页数：8
相关论文
共 50 条
  • [21] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [22] WORK PRODUCTIVITY IN BRAZILIAN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Lopes, N.
    Antonio, J. R.
    Fabricio, L.
    Azulay-Abulafia, L.
    Dias, L. L.
    Pertel, P.
    VALUE IN HEALTH, 2017, 20 (09) : A902 - A902
  • [23] Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab
    Kim, Bo Ri
    Yang, Seungkeol
    Choi, Chong Won
    Youn, Sang Woong
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (02) : 123 - 128
  • [24] Biologicals for moderate-to-severe plaque type psoriasis in pediatric patients
    Libon, Florence
    Lebas, Eve
    De Schaetzen, Virginie
    Sabatiello, Murielle
    De Schepper, Sofie
    Nikkels, Arjen F.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (09) : 947 - 955
  • [25] Patient choice of dosing frequency among moderate-to-severe plaque psoriasis patients with adalimumab, etanercept, and/or ustekinumab experience
    Carter, Chureen
    Farahi, Kamyar
    Johnson, Michael P.
    Olson, William
    Zhang, Mingliang
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB262 - AB262
  • [26] Efficacy of switching from ustekinumab to guselkumab in patients with moderate-to-severe plaque psoriasis: Results from the NAVIGATE study
    Langley, Richard G.
    Tsai, Tsen-Fang
    Flavin, Susan
    Song, Michael
    Randazzo, Bruce
    Wasfi, Yasmine
    Li, Shu
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [27] Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis
    Frampton, James E.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (02) : 295 - 306
  • [28] The management of moderate-to-severe chronic plaque psoriasis
    Tonini, Annalisa
    Panduri, Salvatore
    D'Erme, Angelo M.
    Papadia, Francesca
    Romaneli, Marco
    Krueger, James G.
    Chiricozzi, Andrea
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2017, 152 (05): : 447 - 457
  • [29] Advances in the treatment of moderate-to-severe plaque psoriasis
    Herrier, Richard N.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (09) : 795 - 806
  • [30] Guselkumab for the treatment of moderate-to-severe plaque psoriasis
    Yang, Eric J.
    Sanchez, Isabelle M.
    Beck, Kristen
    Sekhon, Sahil
    Wu, Jashin J.
    Bhutani, Tina
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 333 - 344
12345